Study Fails to Confirm L-Carnitine Benefits in Dialysis Patients

Share this article:

A new meta-analysis has found that L-carnitine does not significantly increase hemoglobin or decrease the required erythropoietin dose in patients on maintenance hemodialysis (MHD), contrary to a previous meta-analysis. L-cartinine, however, significantly decreases serum levels of low-density lipoprotein (LDL) and C-reactive protein (CRP).

Yizhi Chen, MD, of the Chinese People's Liberation Army Medical Academy in Beijing, and collaborators analyzed data from 49 randomized controlled trials examining the effects of L-carnitine in adult MHD patients. L-carnitine decreased the mean LDL level by 5.82 mg/dL and mean CRP level by 3.65 mg/L, the investigators reported online ahead of print in the American Journal of Clinical Nutrition. L-carnitine had no significant effect on triglycerides, total cholesterol, high-density lipoprotein, hemoglobin, hematocrit, albumin, or the required erythropoietin dose.

Share this article:
You must be a registered member of RUN to post a comment.

More in Hemodialysis

Hemodialysis Antibiotic Lock Cuts Infection Risk

Hemodialysis Antibiotic Lock Cuts Infection Risk

A solution of gentamicin and citrate decreased the likelihood of catheter-related infections and mortality.

No Savings With Drug Combo to Prevent Dialysis Catheter Clots

No Savings With Drug Combo to Prevent Dialysis ...

Higher cost of meds for dialysis catheters partially offset by reduced complications.

Interdialytic Weight Gain May Increase Cardiovascular Risks

Interdialytic Weight Gain May Increase Cardiovascular Risks

A 4% or greater increase in dry weight is associated with a 2-fold increased risk of major adverse cardiac and cerebrovascular events.